Document is current
Any future updates will be listed below
-
Authors
Nutman, Amir
Temkin, Elizabeth
Lellouche, Jonathan
Amar Ben Dalak, Maayan
Kaplan, Ella
Lurie-Weinberger, Mor
Dishon Benattar, Yael
Neuberger, Ami
Stern, Anat
Daitch, Vered
Eliakim-Raz, Noa
Durante-Mangoni, Emanuele
Bernardo, Mariano
Iossa, Domenico
Daikos, George
Skiada, Anna
Pavleas, Ioannis
Friberg, Lena
Theuretzbacher, Ursula
Leibovici, Leonard
Paul, Mical
Carmeli, Yehuda
,
Paul, Mical
Dishon Benattar, Yael
Dickstein, Yaakov
Bitterman, Roni
Zayyad, Hiba
Koppel, Fidi
Zak-Doron, Yael
Altunin, Sergey
Andria, Nizar
Neuberger, Ami
Stern, Anat
Petersiel, Neta
Raines, Marina
Karban, Amir
Leibovici, Leonard
Yahav, Dafna
Eliakim-Raz, Noa
Zusman, Oren
Elbaz, Michal
Atamna, Heyam
Daitch, Vered
Babich, Tanya
Carmeli, Yehuda
Nutman, Amir
Adler, Amos
Levi, Inbar
Daikos, George
Skiada, Anna
Pavleas, Ioannis
Antoniadou, Anastasia
Kotsaki, Antigoni
Durante-Mangoni, Emanuele
Andini, Roberto
Iossa, Domenico
Bernardo, Mariano
Cavezza, Giusi
Bertolino, Lorenzo
Giuffre, Giuseppe
Giurazza, Roberto
Cuccurullo, Susanna
Galdo, Maria
Murino, Patrizia
Cristinziano, Adriano
Corcione, Antonio
Zampino, Rosa
Clara Pafundi, Pia
Mouton, Johan
Friberg, Lena
Kristoffersson, Anders
Theuretzbacher, Ursula
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01732250 at ClinicalTrials.govDocuments that mention this clinical trial
Carbapenem-resistant Enterobacterales (CRE) acquisition and molecular characterization following colistin monotherapy and colistin-meropenem combination therapy: findings from the AIDA randomized trial
https://doi.org/10.1186/s13756-025-01651-1
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
https://doi.org/10.1136/bmjopen-2015-009956
-
Funding
Funding for this research was provided by:
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
European Commission (Grant Health-F3-2011-278348)
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 7 October 2025
First Online: 5 November 2025
Declarations
:
: The trial was approved by the ethics committees of the participating hospitals and informed consent was required for participation.
: Y.C. has received grants and personal fees from MSD, Pfizer, Roche, Qpex Pharmaceuticals, and Spero Therapeutics. E.D.M. has received grants and personal fees from Advanz Pharma, Roche, Genentech, Pfizer, Shionogi, Angelini and Abbvie. G.L.D. has received grants and personal fees from Pfizer and MSD. All other authors declare no competing interests.
